{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 56,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/15",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.43,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Improvement in ORR and DCR of binimetinib vs. dacarbazine translated to improvement in PFS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df8d0690-7a1a-4fb7-840a-7236f14d6024",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "NEMO trial (Lancet Oncol (2017) 18: 435-445) benchmarks are most relevant for SC-2 although study was conducted in a 1/2L setting; IO = immuno-oncology. Limited difference in OS between dacarbazine and binimetinib potentially impacted by 46% of binimetinib and 44% of dacarbazine patients receiving subsequent IO after coming off the trial;",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2876c57-6886-4de4-8f9b-e8ced4601d2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.48,
        "x": 0.43,
        "y": 0.25
      },
      "kind": "list",
      "text": "Second line plus: Chemo is currently the approved post-IO therapy; Binimetinib (MEKi) is not approved but is available in the US via a compendial listing and off label use",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7aa8bb5-6edb-44f9-872a-b25da75fa814",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.09,
        "y": 0.25
      },
      "kind": "list",
      "text": "Front line: IO mono or combo (nivolumab, pembrolizumab, nivolumab + ipilimumab)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa6d6094-2548-4233-9f32-74bdd4b6173d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.45,
        "x": 0.45,
        "y": 0.45
      },
      "kind": "table",
      "text": "SOC: Dacarbazine (7% ORR, 24% DCR, 1.5m PFS, 10.1m OS); Binimetinib (15% ORR, 56% DCR, 2.8m PFS, 11.0m OS)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f879d69-8fb2-48d7-9d5a-3253958cf3de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Current approved standard of care post-IO for NRASm metastatic melanoma is chemotherapy (with 7% ORR and 1.5m PFS in 1/2L setting)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca18c644-a684-4230-ae28-d56417d2acf9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "be47d3cb-9446-49ee-b74a-0c8380f06f09",
      "evidence": "The slide presents a problem statement with components such as current approved standard of care, limitations, and alternative treatments.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 6,
      "beatId": "dba801b5-a4b0-4e64-a12d-ace71b366d55",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Challenges in current cancer treatment and unmet needs",
      "beatSlug": "rags-to-riches-early-struggles",
      "evidence": "Slides 6-15 discuss current treatment limitations and unmet needs in cancer",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "843a34f0-1c93-40b5-8e7f-36476533a31f",
      "evidence": "Slides 15-20 discuss current treatment limitations and potential for Erasca's pipeline",
      "position": 1,
      "objective": "Highlight the cost of not addressing unmet needs in cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}